Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biohit OyjLTS:0DRP -0.75%78 3-1 Month Momentum % is 19.07% as of Aug. 19, 2026. GuruFocus rates LTS:0DRP with a GF Score™ of 78/100 and a GF Value™ of €2.69 (Fairly Valued). The stock has 3 warning signs investors should review. Among 847 Medical Devices & Instruments companies, Biohit Oyj ranks better than 90.91% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-19), Biohit Oyj's 3-1 Month Momentum % is 19.07%.
The industry rank for Biohit Oyj's 3-1 Month Momentum % or its related term are showing as below:
LTS:0DRP's 3-1 Month Momentum % is ranked better than 90.91% of 847
companies
in the Medical Devices & Instruments industry
Industry Median: -6.25
vs LTS:0DRP: 19.07
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Biohit Oyj 3-1 Month Momentum % Related Terms
LTS:0DRP vs ABT, SYK, MDT: 3-1 Month Momentum % Comparison
For the Medical Devices subindustry, Biohit Oyj's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biohit Oyj 3-1 Month Momentum % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biohit Oyj's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Biohit Oyj's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biohit Oyj (LTS:0DRP) has a 3-1 Month Momentum % of 19.07% as of Aug. 19, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Biohit Oyj and its competitors. According to the industry distribution chart, Biohit Oyj ranks #77 out of 847 companies in the Medical Devices & Instruments industry, placing it in the top 9.1%.
Is Biohit Oyj's 3-1 Month Momentum % too high?
Biohit Oyj's current 3-1 Month Momentum % is 19.07%. Based on the distribution chart, Biohit Oyj ranks #77 out of 847 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Biohit Oyj has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Biohit Oyj's 3-1 Month Momentum % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Biohit Oyj ranks #77 out of 847 companies for 3-1 Month Momentum %. This places Biohit Oyj in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Devices & Instruments company?
A good 3-1 Month Momentum % depends on the Medical Devices & Instruments industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Biohit Oyj and its competitors. Biohit Oyj's current 3-1 Month Momentum % is 19.07%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biohit Oyj stock overvalued right now?
Based on GuruFocus' analysis, Biohit Oyj (LTS:0DRP) is currently considered Fairly Valued. The stock's GF Value™ is €2.69, compared to a current price of €2.65 — trading 1.5% below its estimated fair value. The current 3-1 Month Momentum % is 19.07%. Biohit Oyj's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Biohit Oyj (LTS:0DRP), the current 3-1 Month Momentum % is 19.07% as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biohit Oyj (LTS:0DRP) Overvalued in 2026?
Based on GuruFocus' analysis, Biohit Oyj stock appears to be undervalued.
The current stock price of €2.65 is trading 1.5% below its estimated GF Value™ of €2.69.
GuruFocus considers Biohit Oyj to be Fairly Valued.
Key valuation signals for LTS:0DRP:
3-1 Month Momentum %: 19.07%
GF Value™: €2.69 vs. price of €2.65 (1.5% below fair value)
No single metric tells the full story. See the LTS:0DRP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biohit Oyj is a globally operating Finnish biotechnology company that develops diagnostic and other health products. Its products include GastroPanel quick test assesses the structure and function of the stomach lining; ColonView quick test is an immunochemical fecal occult blood test (FIT) developed; Acetium capsules protect the stomach lining from carcinogenic acetaldehyde, especially in people with acid-free stomachs. The company's product portfolio consists of diagnostic tests, analysis systems, products binding carcinogenic acetaldehyde into a harmless compound and monoclonal antibodies.
78GF Score
Get the complete analysis for LTS:0DRP
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0DRP has been successfully added to your 
